肺癌 KRASG12C 脑转移的试验、审判和机遇。
Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases.
出版信息
Clin Cancer Res. 2022 Aug 2;28(15):3179-3181. doi: 10.1158/1078-0432.CCR-22-1137.
Abstract
The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRASG12C brain metastases. See related article by Sabari et al., p. 3318.
摘要
KRAS 抑制剂对脑转移的作用仍相对未知。最近在临床前模型上的研究和正在进行的 KRYSTAL-1 期 Ib 临床试验的初步数据支持 adagrasib（MRTX849）穿透中枢神经系统并控制 KRASG12C 脑转移的潜力。详见 Sabari 等人的相关文章，第 3318 页。
相似文献
1
Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases.肺癌 KRASG12C 脑转移的试验、审判和机遇。
Clin Cancer Res. 2022 Aug 2;28(15):3179-3181. doi: 10.1158/1078-0432.CCR-22-1137.
2
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.阿达格拉西布（MRTX849）在脑转移中的活性：KRASG12C 突变型非小细胞肺癌患者的临床前模型和临床数据。
Clin Cancer Res. 2022 Aug 2;28(15):3318-3328. doi: 10.1158/1078-0432.CCR-22-0383.
3
Adagrasib Response Remains Strong in NSCLC.阿达格拉西布在 NSCLC 中的应答仍然强劲。
Cancer Discov. 2022 Aug 5;12(8):OF1. doi: 10.1158/2159-8290.CD-NB2022-0042.
4
Safety and Intracranial Activity of Adagrasib in Patients With -Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series.KRYSTAL-1试验中阿达格拉西布治疗KRAS G12C突变的非小细胞肺癌及未经治疗的中枢神经系统转移患者的安全性和颅内活性：病例系列
JCO Precis Oncol. 2024 Feb;8:e2300447. doi: 10.1200/PO.23.00447.
5
Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.接受阿达格拉西布治疗的 KRASG12C 突变型非小细胞肺癌患者不良反应管理的实用指南。
Oncologist. 2023 Apr 6;28(4):287-296. doi: 10.1093/oncolo/oyad051.
6
Adagrasib's Efficacy Sustained in KRASG12C NSCLC.阿达格拉西布在KRAS G12C非小细胞肺癌中的疗效持续存在。
Cancer Discov. 2023 Nov 1;13(11):OF1. doi: 10.1158/2159-8290.CD-NB2023-0066.
7
A saturation mutagenesis screen uncovers resistant and sensitizing secondary mutations to clinical KRAS inhibitors.一项饱和诱变筛选揭示了对临床KRAS抑制剂产生抗性和敏感性的二次突变。
Proc Natl Acad Sci U S A. 2022 May 3;119(18):e2120512119. doi: 10.1073/pnas.2120512119. Epub 2022 Apr 26.
8
-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges.- 突变型非小细胞肺癌：从过去的努力到未来的挑战。
Int J Mol Sci. 2022 Aug 20;23(16):9391. doi: 10.3390/ijms23169391.
9
Adagrasib in Non-Small-Cell Lung Cancer.阿达格拉西布治疗非小细胞肺癌
N Engl J Med. 2022 Sep 29;387(13):1238-1239. doi: 10.1056/NEJMc2210539.
10
Adagrasib in Non-Small-Cell Lung Cancer. Reply.阿达格拉西布治疗非小细胞肺癌。回复。
N Engl J Med. 2022 Sep 29;387(13):1238-1239. doi: 10.1056/NEJMc2210539.
Zotero 插件